Over the past several months, I have had the honor of treating a number of patients with Schizophrenia. Some of these patients have been classified as having a more vague “schizo-affective” disorder. In either case, Cannabidiol has significant effects in reducing hallucinations, paranoia and other thought disorders associated with schizophrenia.
There are some studies by Dr. Matthew Jones et al. at Bristol University UK, out of England, suggesting that THC may aggravate or even incite this disorder. Further studies have shown this to be untrue, but THC certainly can effect these patients in somewhat unpredictable ways; at times improving and at times worsening symptoms.
On the other hand, CBD or cannabidiol appears to be very effective and safe. We have know for a number of years that CBD does not have much action on the CB1 and CB2 receptors. So, it has been unclear as to how CBD might work in these and other patients.
In this article, a possible mechanism of CBD is discussed. In addition, at the bottom of this post, I have listed all the references for this article.
It appears that CBD increases the Anandamide level in our brains. Again, Anandamide is our internal “endocannabinoid” that is similar in most respects to THC. So, CBD leads to increased Anandamide by decreasing the level of an enzyme, FAAH, that breaks down Anandamide. In summary, CBD blocks the action of the enzyme that breaks down Anandamide. Increased brain and serum Anandamide lead to improved mood and decreased pain.
This may explain why CBD APPEARS to effect cannabinoid receptors, but in fact also largely works by increasing our internal THC or Anandamide. This may also explain the apparent “Reverse Tolerance” that we often see clinically.
Rogers DP, Goldsmith CA. Treatment of schizophrenia in the 21st century: beyond the neurotransmitter hypothesis. Expert Rev Neurother 2009; 9: 47–54. | Article | PubMed |
Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4: 873–884. | Article | PubMed | ISI | CAS |
Leweke FM, Schneider U, Thies M, Münte TF, Emrich HM. Effects of synthetic Δ9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology 1999; 142: 230–235. | Article |
D’Souza CD, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y-T et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558–1572. | Article | PubMed | ISI | CAS |
Morrison PD, Nottage J, Stone JM, Bhattacharyya S, Tunstall N, Brenneisen R et al. Disruption of frontal theta coherence by Delta(9)-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology 2011; 36: 827–836. | Article | PubMed | ISI |
D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57: 594–608. | Article | PubMed | ISI | CAS |
Henquet C, van Os J, Kuepper R, Delespaul P, Smits M, Campo JA et al. Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry 2010; 196: 447–453.
Scatton B, Sanger DJ. Pharmacological and molecular targets in the search for novel antipsychotics. Behav Pharmacol 2000; 11: 243–256. | PubMed |
Eggan SM, Hashimoto T, Lewis DA. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 2008; 65: 772–784. | Article | PubMed | ISI |
Meltzer HY, Arvanitis L, Bauer D, Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004; 161: 975–984. | Article | PubMed | ISI |
Sanofi-Aventis. Efficacy and safety of AVE1625 as a co-treatment with antipsychotic therapy in schizophrenia (CONNECT). ClinicalTrials gov, May 11 2010; edn, vol. NCT00439634. US National Institute of Health, 2010.
Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999; 10: 1665–1669. | Article | PubMed | ISI | CAS |
Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004; 29: 2108–2114. | Article | PubMed | ISI | CAS |
Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 2007; 18: 129–140. | Article | PubMed | ISI | CAS |
Beltramo M, de Fonseca FR, Navarro M, Calignano A, Gorriti MA, Grammatikopoulos G et al. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci 2000; 20: 3401–3407. | PubMed | ISI | CAS |
Seillier A, Advani T, Cassano T, Hensler JG, Giuffrida A. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Int J Neuropsychopharmacol 2010; 13: 373–386.
Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq M-C. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta-9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 1998; 63: PL1–PL6. | Article | PubMed | ISI | CAS |
Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007; 150: 613–623. | Article | PubMed | ISI | CAS |
Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001; 134: 845–852. | Article | PubMed | ISI | CAS |
Zuardi AW, Morais SL, Guimarães FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995; 56: 485–486. | PubMed | ISI | CAS |
Zuardi AW, Hallak JE, Dursun SM, Morais SL, Faria Sanches R, Musty RE et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006; 20: 683–686. | Article | PubMed | CAS |
Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM. Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 2000; 66: 175–181. | Article | PubMed | ISI | CAS |
Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35: 764–774. | Article | PubMed | ISI |
Schreiber D, Harlfinger S, Nolden BM, Gerth CW, Schömig E, Klosterkötter J et al. Determination of anandamide and other fatty acylethanolamides in human serum by electrospray tandem mass spectrometry. Anal Biochem 2007; 361: 162–168.
Giuffrida A, Rodriguez de Fonseca F, Piomelli D. Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal Biochem 2000; 280: 87–93. | Article | PubMed | ISI | CAS |
Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 1999; 156: 610–616. | PubMed | CAS |
Hauschke D, Kieser M. Multiple testing to establish noninferiority of k treatments with a reference based on the ratio of two means. Drug Inf J 2001; 35: 1247–1251.
van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006; 113: 91–95. | PubMed | ISI | CAS |
Committee for proprietary medicinal products (CPMP). Note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia. February 26 1998; CPMP/EWP/559/95, The European Agency for the Evaluation of Medicinal Products, London, 1998.
Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual ‘atypical’ antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159: 180–190. | Article | PubMed | ISI |
Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009; 30: 515–527. | Article | PubMed | ISI |
Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S et al. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 2009; 194: 371–372.
Potvin S, Kouassi E, Lipp O, Bouchard RH, Roy MA, Demers MF et al. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol 2008; 22: 262–269.
De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2003; 2: 5–13. | Article | PubMed |
Ruhrmann S, Schultze-Lutter F, Salokangas RK, Heinimaa M, Linszen D, Dingemans P et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 2010; 67: 241–251. | Article | PubMed | ISI |
Russo E, Burnett A, Hall B, Parker K. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005; 30: 1037–1043. | Article | PubMed | ISI | CAS |
Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092–1101. | Article | PubMed | ISI | CAS |